Who is sponsoring NCT06883383?

NCT06883383 is sponsored by Hannover Medical School.

What condition does NCT06883383 study?

NCT06883383 studies Cardiomyopathy (Ischemic or Non-Ischemic).

Is NCT06883383 still recruiting?

NCT06883383 is currently completed. Last updated 19 March 2025.

Last reviewed 2025-03-19 · How we verify

NCT06883383: SCD-PROTECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Data Analysis and Evaluation of the Incidence of Life-threatening Ventricular Arrhythmias in Patients with Newly Diagnosed Cardiomyopathies of NICM or MI/CAD Origin PROTECTED from SCD by a WCD

Completed Last updated 19 March 2025

What this trial tests

trial in Cardiomyopathy (Ischemic or Non-Ischemic) in 19,598 participants. Completed in 31 December 2023.

Timeline

1 December 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Hannover Medical School
Status	Completed
Study type	OBSERVATIONAL
Enrollment	19,598
Start date	1 December 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Germany

Conditions studied

Cardiomyopathy (Ischemic or Non-Ischemic) — all drugs for Cardiomyopathy (Ischemic or Non-Ischemic) →

Sponsor

Hannover Medical School

Who can join

18 and older, any sex, with Cardiomyopathy (Ischemic or Non-Ischemic). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SCD-PROTECT is an epidemiological, observational, multicenter study to assess the incidence of sudden cardiac arrest/death (SCA/SCD) in patients with newly diagnosed non-ischemic cardiomyopathy or with myocardial infarction/coronary artery disease. Data on SCA/SCD risk in the early phase of disease, especially during medication up-titration while left ventricular ejection fraction is reduced, are sparse.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
Duncker D, Marijon E, Metra M, Piot O, et al · · 2025 · cited 5× · PMID 40879135 · DOI 10.1093/eurheartj/ehaf668

Verify or expand the search:

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06883383 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 19 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06883383.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing